Welcome to our dedicated page for DexCom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on DexCom stock.
DexCom, Inc. reports news about its continuous glucose monitoring and glucose biosensing business for people with diabetes. Company updates commonly cover Dexcom G7 clinical evidence, product roadmap activity, U.S. and international revenue trends, margins, guidance, and presentations at diabetes technology and healthcare investor conferences.
Dexcom news also includes corporate governance developments, board appointments, management presentations, and long-term strategy discussions tied to its CGM portfolio, global commercialization, and innovation in metabolic health.
Dexcom (DXCM) has promoted Executive Vice President and Chief Financial Officer Jereme Sylvain to the additional role of Chief Operating Officer.
In this expanded position, Sylvain will oversee Dexcom’s global operations and quality teams to support the company’s growth vision and focus on operational excellence. He joined Dexcom in 2018 and has served as CFO since 2021, during which time he built a finance leadership team and helped guide growth and margin expansion. Dexcom’s CEO, Jake Leach, described Sylvain as an exceptional leader whose strategic judgment, operational discipline, and customer focus align with the company’s next phase of growth.
Dexcom (DXCM) has appointed Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Boehnlein is a veteran healthcare and finance executive with over 20 years of medical technology experience, most recently serving as Vice President and Chief Financial Officer of Stryker Corporation. He brings expertise in financial leadership, capital allocation, strategic M&A, and operations to support Dexcom’s long-range growth plans in diabetes and metabolic health.
Dexcom (NASDAQ:DXCM) announced that management will present an update on the company at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, starting at approximately 8:00 AM EDT. The presentation will be webcast live, with access links and an archived replay available on the Dexcom Investor Relations website at investors.dexcom.com.
Dexcom (Nasdaq: DXCM) reported second quarter 2026 revenue of $1.308 billion, up 13% year-over-year (12% organic). U.S. revenue grew 11%, while international revenue increased 19% reported and 16% organic.
GAAP gross profit was $830.0 million (63.4% margin) and non-GAAP gross profit was $838.5 million (64.1% margin), both above prior-year levels. GAAP operating income reached $318.3 million (24.3% margin) and non-GAAP operating income was $328.3 million (25.1% margin), each improving 590 basis points versus Q2 2025. GAAP net income was $249.1 million, or $0.64 per diluted share, and non-GAAP net income was $269.1 million, or $0.70 per diluted share.
Dexcom raised its 2026 guidance to revenue of $5.18–$5.25 billion (11–13% growth), non-GAAP gross margin of ~64%, non-GAAP operating margin of ~23.5–24%, and adjusted EBITDA margin of ~31.5–32%. The company reported $1.95 billion in cash, cash equivalents and marketable securities and highlighted positive CONNECT trial results in type 2 diabetes not using insulin and the launch of its updated Stelo app experience.
Dexcom (NASDAQ: DXCM) has been selected by the U.S. Food and Drug Administration as the first participant in the FDA’s Technology-Enabled Meaningful Patient Outcomes (TEMPO) Digital Health Devices Pilot Program, an initiative to evaluate digital health technologies for chronic disease management using real-world evidence.
According to Dexcom, participation will enable an AI-powered glucose health program that integrates data from Dexcom G7 and Stelo with contextual information such as nutrition, activity, sleep and stress. The program is intended to support prediabetes and Type 2 diabetes screening, help improve glycemic control and HbA1c in people with prediabetes, and inform earlier intervention and broader cardiometabolic outcomes, while leveraging Dexcom’s clinician software platform for population-level care personalization.
Dexcom (NASDAQ: DXCM) announced that Health Canada has authorized the Dexcom G7 15 Day continuous glucose monitoring (CGM) system for adults 18+ with diabetes. According to Dexcom, G7 15 Day is the longest‑lasting and most accurate CGM system authorized by Health Canada, offering real-time glucose readings for up to 15.5 days per sensor and reporting an overall MARD of 8.0%.
The system is designed to lower sensor change frequency, simplify diabetes management and reduce waste, while retaining existing G7 features such as waterproof† sensors, direct-to-Apple Watch‡ connectivity, a 12‑hour sensor grace period, Dexcom Clarity app integration, data sharing with caregivers, and customizable alerts. While authorized, Dexcom G7 15 Day is not yet available for purchase in Canada; Dexcom plans education and support for patients and providers ahead of launch and invites Canadians to register online for availability updates.
Dexcom (NASDAQ:DXCM) will release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will host a conference call at 4:30 p.m. Eastern Time, with a concurrent webcast and archived replay on the Dexcom investor relations website.
Dexcom (NASDAQ: DXCM) announced key Stelo milestones at Aspen Ideas: Health. Stelo received expanded FDA clearance for pediatric use in children from age 2 not using insulin. A fully reimagined Stelo app will launch in July in the US, with international rollouts planned in the UK, Australia, New Zealand and South Korea through 2027.
Dexcom (NASDAQ:DXCM) reported results from the CONNECT randomized controlled trial in adults with Type 2 diabetes not using insulin. Using Dexcom G7 CGM led to a 1.6% average A1C reduction (0.9% greater than control), improved time-in-range, lower hyperglycemia, and higher treatment satisfaction over 26 weeks.
Dexcom (NASDAQ:DXCM) highlighted new clinical, product and strategic initiatives at ADA 2026 to broaden continuous glucose monitoring (CGM) use, especially for people with Type 2 diabetes not on insulin.
Key updates include CONNECT trial data, an FDA-cleared reimagined Stelo app, and the planned acquisition of Nutrisense to add personalized nutrition coaching.